HIT! High Impact Clinical Trials – What and Why

7 Feb 2025 2:15 p.m. 3:45 p.m.
Brahmkamal Hall - Plenary Hall
AndreaViecelli Chair University of QueenslandAustralia
VivekKumar Chair Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaIndia

Time Session
2:15 p.m.
2:45 p.m.
Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)
RajivAgarwal Oral Abstract Presenter United States
2:45 p.m.
3:15 p.m.
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
BradRovin Oral Abstract Presenter The Ohio State UniversityUnited States
3:15 p.m.
3:45 p.m.
Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial
KatherineTuttle Oral Abstract Presenter University of Washington School of Medicine, Division of NephrologyUnited States